FDA nod for AADC deficiency gene therapy from PTC
The US Food and Drug Administration (FDA) has granted accelerated approval of PTC Therapeutics’ gene therapy for the treatment of AADC (aromatic L-amino acid decarboxylase) deficiency, making it the first-ever gene therapy approved in the USA that is directly administered to the brain.
US FDA approves PTC Therapeutics' gene therapy for ultra-rare disorder
Nov 13 (Reuters) - The U.S. Food and Drug Administration approved PTC Therapeutics' (PTCT.O), opens new tab gene ... coats in turnaround plan 9:45 AM UTC · Updated ago Reuters, the news and media division of Thomson Reuters, is the world’s largest ...
Joseph Schwartz, an analyst from Leerink Partners, reiterated the Hold rating on PTC Therapeutics (PTCT – Research Report). The ...
Industrial software maker PTC forecast first-quarter revenue below estimates on Wednesday, signaling continued weakness in ...
ROKA -13%.Now read: AcelRx: Ironically, I Misunderstood The... BySeeking Alpha • Sep 26, 2017 Investors shaken by PTC's briefing docs ahead of Ad Com for DMD candidate Translarna; shares down 14 ...
For the quarter, PTC anticipates revenues to be between $598 million and $648 million. Non-GAAP earnings per share (EPS) are expected to be between $1.30 and $1.66. The Zacks Consensus Estimate ...
Barclays raised the firm’s price target on PTC Therapeutics (PTCT) to $43 from $31 and keeps an Equal Weight rating on the shares. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback